 |
|
Prediction of Improvement in Schizophrenia Under Four Phenothiazines
SOLOMON C. GOLDBERG, PhD;
NILS MATTSSON, LLM;
JONATHAN O. COLE, MD;
GERALD L. KLERMAN, MD
Arch Gen Psychiatry. 1967;16(1):107-117.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
THERE are now quite a number of psychotropic agents (reserpine, the phenothiazines, and the butyrophenones) which have been demonstrated to be effective in the treatment of schizophrenic patients. In the course of using these drugs, observations have been made to the effect that certain kinds of schizophrenic patients are more responsive to certain of the drugs, while other schizophrenic patients are more responsive to other drugs. For instance, the patient who is agitated, hostile, and aggressive presumably responds best to chlorpromazine, while the more apathetic and withdrawn patient in need of energizing is said to respond better to one of the piperazine derivatives, such as fluphenazine or trifluoperazine. However, most controlled research until the recent past has been unable to verify these observations; nor has anyone demonstrated that different phenothiazines result in any different clinical effects of any kind, even though clear differences in side
. . . [Full Text PDF of this Article]
Author Affiliations
BETHESDA, MD
From the Psychopharmacology Service Center, National Institute of Mental Health, National Institutes of Health, Bethesda, Md.
Footnotes
Submitted for publication May 2, 1966.
Reprint requests to Clinical Studies Section, Psychopharmacology Research Branch, National Institute of Mental Health, Barlow Bldg, 5454 Wisconsin Ave, Chevy Chase, Md 20015 (Dr. Goldberg).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
